Register for free
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

2.050 -0.030 (-1.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Innate Pharma S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
AstraZeneca Cuts Innate-Partnered Phase 3 Trial In Head & Neck Cancer
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
  
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Good morning, trader! We're starting off Monday with a breakdown of the biggest pre-market stock movers traders will want to watch! 
Via InvestorPlace
Why Celyad Oncology Is Trading Higher By Over 31%; Here Are 29 Stocks Moving Premarket
Gainers MAIA Biotechnology, Inc. (NASDAQ: MAIA) rose 37.9% to $8.00 in pre-market trading after jumping 30% on Friday. The company agreed to initially offer 2.00 million shares to the public at a $5.00... 
Via Benzinga
Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study
From Innate Pharma SA
Via Business Wire
Innate Pharma to Participate in Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development
From Innate Pharma SA
Via Business Wire
Innate Pharma to Participate in Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
67 Biggest Movers From Yesterday
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital. 
Via Benzinga
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer
From Innate Pharma S.A.
Via Business Wire
Outcome of Innate Pharma’s 2022 Annual General Meeting
From Innate Pharma S.A.
Via Business Wire
Innate Pharma to Participate in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
Innate Pharma Reports First Quarter 2022 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Number of Shares and Voting Rights of Innate Pharma as of May 1, 2022
From Innate Pharma SA
Via Business Wire
Innate Pharma Establishes an At-The-Market (“ATM”) Program on Nasdaq
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update
From Innate Pharma SA
Via Business Wire
70 Biggest Movers From Friday
Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners. Vaxxinity, Inc. (NASDAQ: VAXX)... 
Via Benzinga
48 Stocks Moving In Friday's Mid-Day Session
Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS. GTY Technology Holdings Inc. (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
28 Stocks Moving in Friday's Pre-Market Session
Gainers Zymeworks Inc. (NASDAQ: ZYME) rose 40.3% to $6.97 in pre-market trading. Zymeworks 13D filing confirmed earlier reporting of offer letter from Blue Falcons for $10.50 per... 
Via Benzinga
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca
From Innate Pharma SA
Via Business Wire
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 20, 2022
From Innate Pharma SA
Via Business Wire
Innate Pharma Files Its 2021 Universal Registration Document (Document d’enregistrement universel) and 2021 Annual Report on Form 20-F
From Innate Pharma SA
Via Business Wire
Earnings Scheduled For March 24, 2022
Companies Reporting Before The Bell • iHuman (NYSE:IH) is likely to report earnings for its fourth quarter. • Pioneer Muni High Inc (NYSE:MAV) is expected to... 
Via Benzinga
Innate Pharma Reports Full Year 2021 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Innate Pharma FY 2021 Earnings Conference Call On March 24, 2022 At 09:00 AM ET
Innate Pharma (NASDAQ:IPHA) will host a conference call at 09:00 AM ET on March 24, 2022, to discuss FY 2021 earnings results. How to Attend Innate Pharma (IPHA) Conference Call... 
Via Benzinga
Innate Pharma Announces Conference Call and Webcast for Full Year 2021 Financial Results
From Innate Pharma SA
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Innate Pharma (NASDAQ:IPHA) stock increased by 13.7% to $3.32 during Thursday's pre-market session. The market value of their outstanding shares is at $264.6... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS